Lifeboat Foundation

A senior Chinese government official confirmed Friday that authorities ordered laboratories to destroy samples of coronavirus in early January.

Secretary of State Mike Pompeo had accused Chinese officials of ordering the samples’ destruction as part of the regime’s cover-up of the coronavirus outbreak in its early stages.

Pompeo said on April 22 that China “censored those who tried to warn the world, it ordered a halt to testing of new samples, and it destroyed existing samples.” He offered more specificity on May 6, stating that China’s National Health Commission [NHC] ordered virus samples destroyed on Jan. 3.

CloudWalk has raised RMB 1.8 billion (US$254 million) in funding from a group of provincial and municipal funds in China to become the fourth most well-funded biometric facial recognition company in the country, according to a report in Chinese-language publication 36Kr covered by its English-language affiliate KrAsia.

CloudWalk intends to launch an IPO on Shanghai’s Star Market by the end of 2020, according to the report. The company has raised a total of RMB 2.8 billion ($400 million) so far.

CloudWalk provides facial recognition for numerous public agencies, including the Bank of China, Shanghai Pudong Airport, and China Mobile’s brick and mortar stores.

Defense Ministry-run Institute for Biological Research said to prepare further experiments before moving on to human trials, hopes to have finished product within a year.

“In one sense, universities have become victims of their own success at teaching online, but some academics are concerned that continued closures could hurt poorer students without access to computers or study space, while others mourn the loss of face-to-face connection while teaching.” Universities have become bloated cliques. Has Covid shown we don’t need mini-towns and fat fees? Poorer students might welcome online courses at 10% of the cost surely and shorter completion time, surely?

Governments are prioritising reopening schools and businesses over campuses. But some academics fear the impact on disadvantaged students – and on their teaching.

Circa 2019.

Gain of function research was heavily debated amidst many CDC mishaps. It was stopped, and then outsourced to China due to lax regulations. Now we have an outbreak that no one can confirm it’s origin, but the epicenter is in close proximity to a Wuhan lab working on the same pathogen, with direct bat to human transmission.

Knowing this, this story disturbs me, as we have no international protocols and regulations to prevent mishaps. The last thing we need is a lab mishap, and monkeys riding on horses with guns, all pissed off at humans. We are already experiencing the Contagion movie, and biblical plagues like locusts, the last we need is planet of the apes.

Continue reading “Scientists are making human-monkey hybrids in China” »

Plants can produce energy-rich biomass with the help of light, water and carbon dioxide. This is why they are at the beginning of the food chains. But the carnivorous plants have turned the tables and hunt animals. Insects are their main food source.

A publication in the journal Current Biology now sheds light on the secret life of the green carnivores. The plant scientist Rainer Hedrich and the evolutionary bioinformatician Jörg Schultz, both from Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany, and their colleague Mitsujasu Hasebe from the University of Okazaki (Japan) have deciphered and analyzed the genomes of three carnivorous plant species.

They studied the Venus flytrap Dionaea muscipula, which originates from North America, the globally occurring waterwheel plant Aldrovanda vesiculosa and the spoon-leaved sundew Drosera spatulata, which is widely distributed in Asia.

The Food and Drug Administration (FDA) has granted emergency clearance for a coronavirus testing kit that allows people to take a nasal sample in their own homes and send it to a laboratory for diagnostic testing.

The FDA granted the clearance to the company Everlywell, Inc.

Christina Song, an Everlywell spokeswoman told The New York Times, “From the moment that you hit the order button, to the moment that you get the test results on your phone or device, that process is designed to take three to five days.”

As COVID-19 brings the real estate market to a standstill, demand for doomsday bunkers is at an all-time high (or low since the structures are underground). The shelters were once signifiers of fringe prepper communities worried about the coming apocalypse. During the pandemic, they’ve become vacation homes. “People thought we were crazy because they never believed anything like this could happen,” says Vicino. “Now they’re seeing it. Everybody is a believer.”

Survival companies are capitalizing on coronavirus fears to sell bunkers that can withstand the apocalypse. But their claims about the virus are questionable.

The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases.

In December 2019, an outbreak of pneumonia was reported in Wuhan, Hubei province, China, resulting from infection with a novel coronavirus (CoV), severe acute respiratory syndrome (SARS)-CoV-2. SARS-CoV-2 is a novel, enveloped betacoronavirus with phylogenetic similarity to SARS-CoV (1). Unlike the coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU, that are pathogenic in humans and are associated with mild clinical symptoms, SARS-CoV-2 resembles both SARS-CoV and Middle East respiratory syndrome (MERS), with the potential to cause more severe disease. A critical distinction is that CoVs that infect the upper respiratory tract tend to cause a mild disease, whereas CoVs that infect both upper and lower respiratory tracts (such as SARS-CoV-2 appears to be) may cause more severe disease. Coronavirus disease (COVID)-19, the disease caused by SARS-CoV-2, has since spread around the globe as a pandemic.

In the absence of a SARS-CoV-2-specific vaccine or an approved antiviral, a number of antivirals are currently being evaluated for their therapeutic effectiveness. Type I IFNs-α/β are broad spectrum antivirals, exhibiting both direct inhibitory effects on viral replication and supporting an immune response to clear virus infection (2). During the 2003 SARS-CoV outbreak in Toronto, Canada, treatment of hospitalized SARS patients with an IFN-α, resulted in accelerated resolution of lung abnormalities (3). Arbidol (ARB) (Umifenovir) (ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2 [(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate), a broad spectrum direct-acting antiviral, induces IFN production and phagocyte activation. ARB displays antiviral activity against respiratory viruses, including coronaviruses (4).